Given that both attention-deficit hyperactivity disorder (ADHD) and cannabis use are known independent risk factors for psychosis, people with ADHD who consume cannabis may be especially vulnerable. The main objective of the current study was to explore the links between ADHD, cannabis use and psychosis outcomes.
Methods
A systematic review was conducted to examine the risk of psychosis among people with ADHD who are exposed to cannabis. Literature searches were conducted using four electronic bibliographic databases. The findings were synthesised following the synthesis without meta-analysis reporting guideline.
Results
Three studies meeting the inclusion criteria were identified. These studies were heterogeneous in design, and the assessment of the risk of bias found one study to be fair quality and two to be good quality. Two included studies indirectly suggested that cannabis use does not impact the risk of psychosis among people with ADHD, and one study supported cannabis having a similar impact on the risk of psychosis for people with and without ADHD.
Conclusion
There have been very few studies examining the relationship between ADHD, cannabis use, and psychosis. Currently, there is very little evidence to suggest that the risk of psychosis associated with cannabis use is heightened for people diagnosed with ADHD. However, limitations in existing evidence highlight the need for further research on this topic.
AyanoGDemelashSGizachewY, et al.The global prevalence of attention deficit hyperactivity disorder in children and adolescents: an umbrella review of meta-analyses. J Affect Disord2023; 339: 860–866. https://doi.org/10.1016/j.jad.2023.07.071
3.
AyanoGTsegayLGizachewY, et al.Prevalence of attention deficit hyperactivity disorder in adults: umbrella review of evidence generated across the globe. Psychiatry Res2023; 328: 115449. https://doi.org/10.1016/j.psychres.2023.115449
4.
KatzmanMABilkeyTSChokkaPR, et al.Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry2017; 17: 302. https://doi.org/10.1186/s12888-017-1463-3
5.
ChoiWSWooYSWangSM, et al.The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: a systematic literature review. PLoS One2022; 17: e0277175. https://doi.org/10.1371/journal.pone.0277175
6.
FranciscoAPLethbridgeGPattersonB, et al.Cannabis use in attention - deficit/hyperactivity disorder (ADHD): a scoping review. J Psychiatr Res2023; 157: 239–256. https://doi.org/10.1016/j.jpsychires.2022.11.029
7.
NourredineMGeringAFourneretP, et al.Association of attention-Deficit/Hyperactivity disorder in childhood and adolescence with the risk of subsequent psychotic disorder: a systematic review and meta-analysis. JAMA Psychiatry2021; 78: 519–529. https://doi.org/10.1001/jamapsychiatry.2020.4799
8.
Di FortiMQuattroneDFreemanTP, et al.The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry2019; 6: 427–436. https://doi.org/10.1016/S2215-0366(19)30048-3
9.
MarconiADi FortiMLewisCM, et al.Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull2016; 42: 1262–. https://doi.org/10.1093/schbul/sbw003
MurrieBLappinJLargeM, et al.Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull2020; 46: 505–516. https://doi.org/10.1093/schbul/sbz102
12.
LawrenceDHafekostJJohnsonSE, et al.Key findings from the second Australian child and adolescent survey of mental health and wellbeing. Aust N Z J Psychiatr2016; 50: 876–886. https://doi.org/10.1177/0004867415617836
OhHKoyanagiAKelleherI, et al.Psychotic experiences and disability: findings from the collaborative psychiatric epidemiology surveys. Schizophr Res2018; 193: 343-347. https://doi.org/10.1016/j.schres.2017.07.049
15.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71. https://doi.org/10.1136/bmj.n71
16.
ClarkJMSandersSCarterM, et al.Improving the translation of search strategies using the polyglot search translator: a randomized controlled trial. J Med Libr Assoc2020; 108: 195-207. https://doi.org/10.5195/jmla.2020.834
ForteAJGuliyevaGMcLeodH, et al.The impact of optimism on cancer-related and postsurgical cancer pain: a systematic review. J Pain Symptom Manag2022; 63: e203–e211. https://doi.org/10.1016/j.jpainsymman.2021.09.008
19.
CampbellMMcKenzieJESowdenA, et al.Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. Br Med J2020; 368: l6890. https://doi.org/10.1136/bmj.l6890
20.
JeyapalanJSassiPMittendorferRE, et al.Characteristics of incident substance-induced psychosis compared to first-episode psychotic disorders: a nationwide register-linkage study from Sweden. Schizophr Res2024; 264: 526–533. https://doi.org/10.1016/j.schres.2024.01.033
21.
VitielloBPerezAGArnoldLE, et al.Psychotic symptoms in attention-Deficit/Hyperactivity disorder: an analysis of the MTA database. J Am Acad Child Adolesc Psychiatry2017; 56: 336–343. https://doi.org/10.1016/j.jaac.2017.01.016
22.
MarwahaSThompsonABebbingtonP, et al.Adult attention deficit hyperactivity symptoms and psychosis: epidemiological evidence from a population survey in England. Psychiatry Res2015; 229: 49–56. https://doi.org/10.1016/j.psychres.2015.07.075
23.
ChengNBryceSTakagiM, et al.The prevalence of attention deficit hyperactivity disorder in psychotic disorders: systematic review and meta-analysis. Schizophr Bull2025; 51: 1514–1528. https://doi.org/10.1093/schbul/sbae228
24.
RicciVBarresiMDi SalvoG, et al.Neurodevelopmental, pharmacological and substance use factors in the association between ADHD and first-episode non-affective psychosis: a systematic review. Early Interv Psychiatry2026; 20: e70123. https://doi.org/10.1111/eip.70123
25.
Dela PenaIGevorkianaRShiWX. Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. Eur J Pharmacol2015; 764: 562-570. https://doi.org/10.1016/j.ejphar.2015.07.044
26.
KesbyJPEylesDWMcGrathJJ, et al.Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry2018; 8: 30. https://doi.org/10.1038/s41398-017-0071-9
27.
MoranLVOngurDHsuJ, et al.Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med2019; 380: 1128–1138. https://doi.org/10.1056/NEJMoa1813751
28.
BahjiAStephensonC. International perspectives on the implications of cannabis legalization: a systematic review & thematic analysis. Int J Environ Res Publ Health2019; 16: 20190826. https://doi.org/10.3390/ijerph16173095
29.
ChiuVLeungJHallW, et al.Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology2021; 193: 108610. https://doi.org/10.1016/j.neuropharm.2021.108610
30.
GilmanJM. Association of cannabis legalization with prevalence of schizophrenia-challenges of attributing biological causality to policy change. JAMA Netw Open2025; 8: e2457876. https://doi.org/10.1001/jamanetworkopen.2024.57876
31.
HallWStjepanovicDCaulkinsJ, et al.Public health implications of legalising the production and Sale of cannabis for medicinal and recreational use. Lancet2019; 394: 1580–1590. https://doi.org/10.1016/S0140-6736(19)31789-1
32.
MyranDTPuglieseMHarrisonLD, et al.Changes in incident schizophrenia diagnoses associated with cannabis use disorder after cannabis legalization. JAMA Netw Open2025; 8: e2457868. https://doi.org/10.1001/jamanetworkopen.2024.57868
33.
CooperREWilliamsESeegobinS, et al.Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol2017; 27: 795–808. https://doi.org/10.1016/j.euroneuro.2017.05.005
34.
LargeM. Letter to the editor: letter to the editor regarding 'psychotogenic potential of prescribed drugs. Aust N Z J Psychiatr2024; 58: 188. https://doi.org/10.1177/00048674231211501
LupkeKGerardAMurdochB, et al.Impacts of medicinal cannabis on an early psychosis service. Australas Psychiatry2024; 32: 164. https://doi.org/10.1177/10398562231222818
37.
Garcia-ArgibayMChangZBrikellI, et al.Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals. Lancet Psychiatry2025; 12: 131–139. https://doi.org/10.1016/S2215-0366(24)00396-1
38.
KesslerRCAdlerLAmesM, et al.The world health organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med2005; 35: 245–256. https://doi.org/10.1017/s0033291704002892
39.
CharlsonFJFerrariAJSantomauroDF, et al.Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull2018; 44: 1195–1203. https://doi.org/10.1093/schbul/sby058
40.
McGrathJJSahaSAl-HamzawiA, et al.Psychotic experiences in the general population: a cross-national analysis based on 31,261 respondents from 18 countries. JAMA Psychiatry2015; 72: 697–705. https://doi.org/10.1001/jamapsychiatry.2015.0575
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
